Skip to main content

Genscript Biotech

GenScript Biotech Corporation is a Chinese biotechnology enterprise that provides life sciences contract research reagents, biological development services, and cell therapy products worldwide. The company operates through four main business segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products through Bestzyme, and Cell Therapy through Legend Biotech. Its primary revenue drivers consist of gene synthesis and peptide manufacturing services, bioprocess development fees, milestone and royalty payments from CAR-T cell therapies, and commercial sales of industrial enzymes. GenScript Biotech holds a leading position in the global gene synthesis services market, catering to academic, pharmaceutical, and biotech research clients across North America, Europe, and the Asia-Pacific region. The enterprise focuses on expanding its clinical CAR-T cell therapy commercialization, scaling biological manufacturing facilities, advancing contract development capabilities, and innovating synthetic biology applications. GenScript Biotech Corporation is headquartered in Nanjing, China, and its common shares are publicly listed and traded on the Hong Kong Stock Exchange.

13 of the funds FundTelligence covers report a position in Genscript Biotech.

Legal name
Genscript Biotech Corp
Sector
Health Care
Country
China
Funds holding it
13

Funds holding Genscript Biotech

Showing the 8 largest of 13 funds holding it.

Loading...